Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Lauren Lieberman downgraded the rating for PepsiCo, Inc.

SoundHound is presenting at Nvidia's GTC event this week. The company's technology will also be featured by Oracle at GTC. Join Nic Chahine live on Wednesday, March 19, at 6 PM ET for a step-by-step breakdown of how to to capitalize on post-Fed volatility and manage risk in this fast-moving ...

Trump considers approving Nippon Steel's $14.1B bid for U.S. Steel after Biden blocked the merger over national security concerns. Nippon Steel and U.S. Steel gain 21-day extension to negotiate with the U.S. government, avoiding immediate legal resolution.

Blue Orca Capital releases a short report on Tuesday, calling Hesai group a "Chinese scam." "In our opinion, it is completely untrustworthy as a business and uninvestable as a stock," the short seller says. Our government trade tracker caught Pelosi's 169% AI winner.

A Hyperliquid trader banked nearly $4 million profit on a massive leveraged Bitcoin short, then proceeded to bet on MELANIA.

Deep-pocketed investors have adopted a bearish approach towards e.l.f. Beauty ELF, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

Financial giants have made a conspicuous bullish move on Nike. Our analysis of options history for Nike NKE revealed 22 unusual trades. Delving into the details, we found 63% of traders were bullish, while 18% showed bearish tendencies.

Investors with a lot of money to spend have taken a bullish stance on Reddit RDDT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

FDA grants Fast Track designation to J&J's nipocalimab for moderate-to-severe Sjögren's disease, boosting its regulatory pathway. Phase 2 trial shows over 70% improvement in disease activity at Week 24 and IgG reductions of more than 77% with nipocalimab.

Silgan Hldgs's SLGN short percent of float has fallen 4.0% since its last report. The company recently reported that it has 2.89 million shares sold short, which is 3.12% of all regular shares that are available for trading.